Epidemiology, "Ricardo Gutiérrez" Children's Hospital, Buenos Aires, Argentina, 4 "Ricardo Gutiérrez" Children's Hospital, Buenos Aires, Argentina, 5 Virology, "Ricardo Gutiérrez" Children's Hospital, Buenos Aires, Argentina Session: 248. Pediatric Viral Infections Saturday, October 6, 2018: 12:30 PM Background. Paranfluenza virus (PIV) is an important cause of acute lower respiratory tract infection (ALRI), hospitalization and mortality in children. The aims of this study were to describe the clinical-epidemiologic pattern and infection factors associated with PIV.
Methods. Prospective, cross-sectional study of patients admitted for ALRI 2000-2017, diagnosed with respiratory syncytial virus, adenovirus, influenza or parainfluenza by fluorescent antibody (FA) or real-time polymerase chain reaction (RT-PCR) assay of nasopharyngeal aspirates.
Results. From a total of 15,451 patients included, 13,033 were tested and 45%(5831) had positive samples; RSV was predominant (81.3%,4738) all through the study period, followed by IF: 7.6% (440), PIF 6.9% (402) and AV: 4.3%(251). PIV followed a seasonal epidemic pattern predominantly during spring months (September-October). The median age of cases was 8 months (IQR: 4-13 months); 54% of cases were males. The most frequent clinical presentation was bronchiolitis (61%); 53% had previous admissions for respiratory causes, 9% were readmissions. Comorbidity was found in 59.4%: recurrent respiratory disease (47.8%), congenital heart disease (5.7%), chronic neurological disease (6.5%); 8.5% were malnourished, 23% born preterm and 3.3% immunosuppressed; 23.5% had complications, 10.6% hospital-acquired infections. Lethality was 3.5% (14/396).
The following were independent predictors for PIF infection: recurrent respiratory disease odds ratio ( Background. Human parainfluenza viruses (HPIVs) are one of common causes of respiratory tract infections in children. Among the four serotypes (HPIVs 1-4), little is known about the epidemiology and clinical characteristics of HPIV-4. The aim of this study was to identify the epidemiology and the characteristics of HPIV-4 compared with HPIVs 1-3 in Korean children.
Methods. We reviewed medical records of children with HPIV who had been admitted at Seoul National University Children's Hospital during 2015-2017. Detection of respiratory viruses in nasopharyngeal aspirates was performed using multiplex reverse transcription polymerase chain reaction. Patients who had underlying medical conditions such as chronic respiratory disease, immunodeficiency, congenital heart disease, or concurrent viral infections were excluded.
Results. Of 12,539 samples, 586 (8.1%) were positive for HPIV. By the exclusion criteria, 137 (23.4%) were finally included: 46 (33.6%) for HPIV-3, 34 (24.8%) for HPIV-1 and -4 respectively, 23 (16.8%) for HPIV-2. During the study period, two seasonal outbreaks were observed in each serotype. HPIV-1 was prevalent in September 2015 and August 2016, while HPIV-2 in August 2015 and July 2017. The peak of HPIV-3 infection occurred in July 2016 and May 2017. HPIV-4 was mostly infected from August to September in 2015 and in June 2017. Regardless of serotypes, HPIV was predominantly observed in boys and among children less than 5 years of age (70%); the median age in HPIV-4 was 3.1 (0-18) years. The most common clinical presentation was cough in all serotypes (78.7-88.2%). Sore throat was mainly presented in HPIV-4 infected patients compared with other serotypes (11.8%; P = 0.029). HPIV-4 infection was more often diagnosed as bronchiolitis (32.4%) compared with HPIV-1 (8.8%; P = 0.016) and -2 (8.7%; P = 0.037). Croup was most frequently diagnosed in children with HPIV-2 (21.7%), but no patients with HPIV-4 had croup (P = 0.008).
Conclusion. We observed seasonal peak in HPIV-4 from late spring to autumn. Lower respiratory tract infection was main clinical manifestation in HPIV-4 among hospitalized patients and HPIV-4 is a common respiratory pathogen causing significant morbidity in Korean children during 2015-2017.
Disclosures. Background. Studies suggest that RSV infection early in life is associated with the development of recurrent wheezing, yet, information on large population-based studies among US full-term healthy infants is incomplete. The objective of this study was to evaluate the risk of developing post-RSV recurrent wheezing/ asthma during childhood among full-term infants in a US commercially insured population.
Methods. Retrospective, observational study used data from Truven MarketScan Commercial Claims and Encounters Database (January 1, S700 • OFID 2018:5 (Suppl 1) • Poster Abstracts 2000-December 31, 2016) to identify full-term infants with and without a RSV diagnosis in the first year of life (RSV and non-RSV cohorts respectively). Infants were excluded if they had any of the following: prematurity (<37 weeks' gestation), low birth weight, small for gestational age, congenital heart or chronic lung disease, asthma or wheezing; or had received palivizumab. At least 2 years' continuous follow-up post birth was required throughout the ≤5-year follow-up period. RSV/non-RSV infants were 1:1 matched for gender, region and health plan type. Cumulative incidence of recurrent wheezing or asthma was identified by ICD-9/10 codes, through 1, 2, 3 and 4 years (Y)' post-index (1 year after birth) follow-up, and analyzed using conditional logistic regression.
Results. Matched RSV/non-RSV pairs totaled 38,494 (Y1), 25,603 (Y2), 17,429 (Y3), and 11,921 (Y4) for the years' follow-up. Demographic characteristics, birth year and month were evenly represented between cohorts. Other infections during the perinatal period were more common in the RSV vs. the non-RSV cohort (5.4% vs. 3.2%; P < 0.0001), as were other respiratory conditions (5.8% vs. 2.6%; P < 0.0001), and antibiotic use (76.7% vs. 44.7%; P < 0.0001). Rates of influenza and pneumococcal vaccinations were comparable between cohorts. Cumulative incidence of recurrent wheezing or asthma in the RSV cohort was more than two-fold higher compared with the non-RSV cohort for each follow-up period (P < 0.001) (Figure 1) .
Conclusion. Healthy, full-term, commercially insured children infected with RSV during the first year of life had from 2.2-to 3.6-fold increased risk of developing recurrent wheezing or asthma in the next 1-4 years. This reveals an important medical need for interventions targeting RSV infection in infants. Saturday, October 6, 2018: 12:30 PM Background. RSV is the main agent that causes Acute Lower Respiratory Tract Infection(ALRI) in children. Preterm infants(PT) have a higher risk of hospitalization and complications associated with RSV infection. The aim of this study was to describe epidemiology, clinical pattern and risk factors associated to RSV infection in PT infants.
Methods. Prospective, Cross-sectional study of patients admitted for ALRI, 2000-2017. Virological diagnosis was made by fluorescent antibody assay of nasopharyngeal aspirates or RT-PCR. We compared epidemiological and clinical features, complications and lethality between full term(FT) and PT infants. Logistic regression was performed to establish lethality risk factors in PT.
Results. A total of 15,451 patients included, 13,033 were tested and 45% (5,831) had positive samples; RSV was predominant (81.3%, 4,738) all through the study period showing a seasonal epidemic pattern (May-July); 14% (655) were PT. Congenital cardiopathy OR = 3.41(1.12-10.3), P = 0.003 and perinatal respiratory history OR = 3.1(1.6-6.1), P < 0.001 were the independent predictors for VSR lethality in PT.
